This week highlighted both the opportunities and risks within Pfizer’s oncology business. 📊
A Phase 3 setback for sigvotatug vedotin in lung cancer underscores the challenges of drug development and increases pressure on Pfizer’s late-stage pipeline to deliver meaningful growth. Meanwhile, a new FDA approval for IBRANCE expands its role in breast cancer treatment and demonstrates the continued importance of established products in supporting the company’s oncology portfolio.
Could this balance of setbacks and successes alter Pfizer’s long-term investment case?
3
Cookies allow you to use this website normally and customize your experience on this website.
